Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

International study (n=520) found adjuvant chemotherapy (AC), vs no AC, was associated with improved survival in node-positive disease (median overall survival, 26 vs 13 months; HR, 0.41; 95% CI, 0.22-0.75;) but not node-negative disease. (38 vs 54 months; 0.85; 0.35-2.10).


JAMA Oncology